
OPRX
USDOptimizeRx Corporation Common Stock
Real-time Price
Price Chart
Key Metrics
Market Metrics
Open
$18.900
High
$19.383
Low
$18.689
Volume
0.42M
Company Fundamentals
Market Cap
356.4M
Industry
Health Information Services
Country
United States
Trading Stats
Avg Volume
0.37M
Exchange
NCM
Currency
USD
52-Week Range
AI Analysis Report
Last updated: Oct 30, 2025OPRX Analysis: Navigating OptimizeRx's Volatile Growth Path
Recent Price Movements
- July-August Transition: Shares jumped 37% on August 8 (12.84→17.30) with volume 5x average
- September Rally: Steady climb from 17.16 (Sept 2) to 20.51 (Sept 29) - 19.5% gain
- Current Position: Trading at $20.56 (Oct 29) after hitting $22.25 weekly high
- Pattern Alert: 3 failed attempts to hold above $22 since late September
Key Catalysts
- October 10 Analyst Boost: JMP Securities raised target to $23 (+15% from current)
- AI Prediction Signals:
- Short-term projections: +1.1% (D1), +1.7% (D2), +2.5% (D3)
- High-confidence bullish signal (81.1% AI confidence)
- Volume Surges: 3 recent spikes (584k on Aug 28, 662k on Sept 29, 421k on Oct 24)
Strategic Considerations
Strengths
- Explosive revenue growth (55.2% YoY)
- Strong institutional interest (4.9x average volume days)
- Healthcare tech positioning in growing sector
Concerns
- Profitability challenges (Negative ROE: -8.2%)
- Heavy debt load (24.29 Debt/Equity ratio)
- Technical resistance at $22 level
Actionable Insights
- Entry Window: Current price ($20.56) near support level ($20.55)
- Trade Parameters:
- Stop Loss: $18.48 (10% downside protection)
- Take Profit: $22.50 (9.4% upside)
- Alternative Entries: $20.64-$21.08 range
- Holding Strategy: 1-2 week horizon aligns with AI predictions
Final Perspective
OptimizeRx presents a high-growth opportunity tempered by financial health concerns. The combination of analyst upgrades, AI bullishness, and technical support near current levels creates a favorable risk/reward scenario for short-term traders. Long-term investors should monitor debt management and profitability improvements.
Disclaimer: This analysis references historical data and AI predictions that may not reflect future performance. Consult a financial advisor before making investment decisions. Past performance does not guarantee future results.
Related News
JMP Securities Maintains Market Outperform on OptimizeRx, Raises Price Target to $23
JMP Securities analyst Constantine Davides maintains OptimizeRx with a Market Outperform and raises the price target from $20 to $23.
AI PredictionBeta
AI Recommendation
Updated at: Nov 4, 2025, 05:09 PM
65.0% Confidence
Risk & Trading
Entry Point
$19.62
Take Profit
$20.97
Stop Loss
$17.52
Key Factors
Related Stocks
SREA
DBA Sempra 5.750% Junior Subordinated Notes due 2079
ZIM
ZIM Integrated Shipping Services Ltd. Ordinary Shares
FFIE
Faraday Future Intelligent Electric Inc.
TNK
Teekay Tankers Ltd.
ATRO
Astronics Corporation
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.